论文部分内容阅读
目的探讨caveolin-1的表达情况及其与膀胱癌病理分级及临床分期的关系。方法用SABC免疫组织化学法分析63例膀胱癌组织及15例正常膀胱粘膜中caveolin-1表达,结合临床病理资料作统计分析。结果正常膀胱粘膜中caveolin-1无表达,膀胱癌组织中caveolin-1阳性率达34.92%。其中G1、G2、G3阳性率分别为0%、2.86%、54.28%,病理分级间比较有显著性差异(P<0.01);临床分期Ta～T4阳性率分别为0%、25%、52.94%、40%、50%,各期间比较差异有统计学意义(P<0.05)。结论提示caveolin-1在膀胱癌具有高表达,且与其病理分级及临床分期有一定的关系,可能是膀胱癌的一种肿瘤标记物。
Objective To investigate the expression of caveolin-1 and its relationship with the pathological grade and clinical stage of bladder cancer. Methods SABC immunohistochemical analysis of 63 cases of bladder cancer and 15 cases of normal bladder mucosa caveolin-1 expression, combined with clinical and pathological data for statistical analysis. Results There was no expression of caveolin-1 in normal bladder mucosa. The positive rate of caveolin-1 in bladder cancer was 34.92%. The positive rates of G1, G2 and G3 were 0%, 2.86% and 54.28%, respectively. The positive rates of Ta ~ T4 in clinical stage were 0%, 25% and 52.94% respectively (P <0.01) , 40%, 50% respectively. There was significant difference between each period (P <0.05). The conclusion suggests that caveolin-1 is highly expressed in bladder cancer, and has a certain relationship with its pathological grade and clinical stage, which may be a tumor marker of bladder cancer.